NASDAQ: COGTCogent Biosciences Inc Stock
$37.93+0.62 (+1.66%)
Updated Aug 14, 2026
COGT Price
$37.93
Fair Value Price
$0.37
Market Cap
$6.58B
52 Week Low
$11.53
52 Week High
$43.73
P/E
-17.56x
P/B
12.36x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$377.18M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.57
Operating Cash Flow
-$308M
Beta
1.22
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
COGT Overview
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine COGT's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
COGT
Ranked#269 of 461
Ranked#269 of 461
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.83 | A | |
| $114.47 | A | |
| $347.48 | A |
Be the first to know about important COGT news, forecast changes, insider trades & much more!
COGT News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how COGT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
COGT ($37.93) is overvalued by 10,273.72% relative to our estimate of its Fair Value price of $0.37 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
COGT ($37.93) is not significantly undervalued (10,273.72%) relative to our estimate of its Fair Value price of $0.37 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
COGT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more COGT due diligence checks available for Premium users.
Valuation
COGT fair value
Fair Value of COGT stock based on Discounted Cash Flow (DCF)
Price
$37.93
Fair Value
$0.37
Overvalued by
10,273.72%
COGT ($37.93) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
COGT ($37.93) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
COGT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
COGT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-17.56x
Industry
15.42x
Market
15.97x
COGT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
12.36x
Industry
5.62x
COGT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
COGT's financial health
Profit margin
Revenue
$0.0
Net Income
-$96.4M
Profit Margin
0%
COGT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$834.5M
Liabilities
$302.2M
Debt to equity
0.57
COGT's short-term assets ($804.82M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
COGT's short-term assets ($804.82M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
COGT's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
COGT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$77.3M
Investing
$14.3M
Financing
$3.0M
COGT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
COGT vs Biotech Stocks
Cogent Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.